Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

NAFLD as a driver of chronic kidney disease

(2020) Christopher D. Byrne et al.   JOURNAL OF HEPATOLOGY

Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling

(2020) Jesse D. Kirkpatrick et al.   Science Translational Medicine

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

(2020) Olivier Govaere et al.   Science Translational Medicine

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2019) Peter J. Eddowes et al.   GASTROENTEROLOGY

Non-invasive early detection of acute transplant rejection via nanosensors of granzyme B activity

(2019) Quoc D. Mac et al.   Nature Biomedical Engineering

From NASH to HCC: current concepts and future challenges

(2019) Quentin M. Anstee et al.   Nature Reviews Gastroenterology & Hepatology

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

(2019) Naim Alkhouri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

(2019) Hannah K. Drescher et al.   Cells

Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease

(2019) Robert N Helsley et al.   eLife

Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis

(2018) Ma Ai Thanda Han et al.   Clinical Gastroenterology and Hepatology

Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis

(2018) Cyrielle Caussy et al.   HEPATOLOGY

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science

(2018) Mohammad Shadab Siddiqui et al.   HEPATOLOGY

Combination of an FXR agonist and an ACC inhibitor increases anti-fibrotic efficacy in rodent models of NASH

(2018) J. Bates et al.   JOURNAL OF HEPATOLOGY

Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers

(2018) Eduardo Vilar-Gomez et al.   JOURNAL OF HEPATOLOGY

Matrix metalloproteinases and liver fibrosis (translational aspects)

(2018) Elke Roeb   MATRIX BIOLOGY

Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions

(2018) Paul Kennedy et al.   RADIOLOGY

Classification of prostate cancer using a protease activity nanosensor library

(2018) Jaideep S. Dudani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

(2017) Rohit Loomba et al.   HEPATOLOGY

Proteases Revisited: Roles and Therapeutic Implications in Fibrosis

(2017) Jakub Kryczka et al.   MEDIATORS OF INFLAMMATION

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis

(2017) Maria Ryaboshapkina et al.   Scientific Reports

Cathepsin D regulates lipid metabolism in murine steatohepatitis

(2017) Tom Houben et al.   Scientific Reports

Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children

(2016) David E. Kleiner et al.   Clinics in Liver Disease

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

(2016) Amon Asgharpour et al.   JOURNAL OF HEPATOLOGY

Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance

(2016) Erik JM Toonen et al.   MOLECULAR MEDICINE

Fibroblast activation protein (FAP) as a novel metabolic target

(2016) Miguel Angel Sánchez-Garrido et al.   Molecular Metabolism

Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers

(2016) Katharine M. Irvine et al.   PLoS One

Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention

(2016) Sofie M. A. Walenbergh et al.   Scientific Reports

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples

(2015) M. H. Veldman-Jones et al.   CANCER RESEARCH

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

What is the future of PEGylated therapies?

(2015) Magdalena Swierczewska et al.   EXPERT OPINION ON EMERGING DRUGS

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Mathematical framework for activity-based cancer biomarkers

(2015) Gabriel A. Kwong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Practice patterns in NAFLD and NASH: real life differs from published guidelines

(2015) Mary E. Rinella et al.   Therapeutic Advances in Gastroenterology

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

(2014) Pierre Bedossa et al.   HEPATOLOGY

The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling

(2014) Kohei Uchimura et al.   Nature Communications

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis

(2013) Masahiko Matsumoto et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Suppressed mitochondrial biogenesis in folic acid-induced acute kidney injury and early fibrosis

(2013) L. Jay Stallons et al.   TOXICOLOGY LETTERS

Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases

(2012) Hidenori Toyoda et al.   BIOMARKERS

Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease

(2012) Gabriel A Kwong et al.   NATURE BIOTECHNOLOGY

Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

(2010) Elizabeth M. Brunt et al.   HEPATOLOGY

BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy

(2010) K. L. Hudkins et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection

(2009) Fabio D’Amico et al.   ACTA HISTOCHEMICA

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2009) Amy G. Shah et al.   Clinical Gastroenterology and Hepatology

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

(2009) Ariel E. Feldstein et al.   HEPATOLOGY

Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential

(2008) Anna Moles et al.   HEPATOLOGY

Liver biopsy: The best, not the gold standard

(2008) Pierre Bedossa et al.   JOURNAL OF HEPATOLOGY